Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 13/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 13/20 | 0.37 |
| ▸ | WNT1 | P04628 | 7/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | CLK3 | P49761 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136420 | 0.89 | GSK3B (0.39) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL25136182 | 0.87 | SCN9A (0.45) | SCN9AGSK3BDYRK1AWNT1IDH1 | |
| SCHEMBL25136061 | 0.83 | CD38 (0.46) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL30182658 | 0.83 | TAS1R3 (0.42) | GSK3BDYRK1ACD38 | |
| SCHEMBL29182259 | 0.83 | TAS1R3 (0.42) | GSK3BDYRK1ACD38 | |
| SCHEMBL25136296 | 0.83 | TAS1R3 (0.42) | GSK3BDYRK1ACD38 | |
| SCHEMBL31722438 | 0.82 | HDAC4 (0.40) | SCN9AGSK3BDYRK1AWNT1 | |
| SCHEMBL30363923 | 0.80 | GSK3B (0.37) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL25135950 | 0.80 | RORC (0.37) | CYP1A2CD38KCNH2 | |
| SCHEMBL25135976 | 0.80 | CD38 (0.46) | GSK3BDYRK1AWNT1CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | SCN9A 1396/4885GSK3B 395/4885DYRK1A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.